Business Context and Reporting Period
This Form 8-K is filed by Landec Corporation (not Lifecore Biomedical, Inc.) for the reporting period ending March 28, 2002. The filing reports a material "Other Event" regarding a private placement financing transaction.
Key Financial Metrics
The filing details a capital raise rather than operational performance metrics. Key financial figures include:
- Total Financing Proceeds: $8,000,061.50
- Shares Issued: 2,580,665 shares of Common Stock
- Price Per Share: $3.10
- Placement Agent Fee: $640,000 paid to Roth Capital Partners, LLC
- Initial Proceeds Received (March 28): $6,000,062.40 (1,935,504 shares)
- Expected Proceeds (April 5): $1,999,999.10 (645,161 shares)
The filing text does not provide clear values for revenue, profit, cash flow, margins, or existing debt levels.
Material Changes
The primary material change is the increase in equity capital and cash liquidity resulting from the private placement. The company completed the sale of approximately 75% of the authorized shares on March 28, 2002, with the remainder scheduled for April 5, 2002.
Outlook, Risks, and Management Commentary
Management Commentary: The company entered into Subscription Agreements with accredited institutional investors to secure funding. A Registration Rights Agreement was signed to facilitate the resale of these shares, with a registration statement expected to be filed within 30 days of March 28, 2002.
Risks and Contingencies: The filing does not explicitly list new risks, though the reliance on a private placement suggests a need for immediate liquidity. The transaction is contingent upon the completion of the second tranche of share sales on April 5, 2002.
Investor Verification Checklist
- Verify the actual receipt of the remaining $1,999,999.10 scheduled for April 5, 2002.
- Confirm the filing of the Registration Statement for the resale of shares within the 30-day window.
- Review the attached Subscription Agreements (Exhibit 10.1) for any restrictive covenants or dilution protections.
- Check subsequent filings for the impact of this capital raise on the company's cash position and operational runway.